Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by investright12on Apr 08, 2020 8:00pm
324 Views
Post# 30892374

ABOUT TO EXPLODE- large shareholders

ABOUT TO EXPLODE- large shareholdersThis baby is set to explodee in the coming weeks...Test results from Korea
Start of clinical triqls in Korea 
Potential Goverment or Bill Gates funding
Start of strong IR programs

The companyis  well funded as it did two recent financings for over $3M...Biggest subscriber was Grow Max Capital. C.GRO,  GRO is n investment issuer nd they own 8M shares of AGN. https://growmaxcorp.com

Also BullRun Capitql has a big position of 5.5M shares as well.. Both Growmax qnd BullRun are supporters of AGN from the start.

I hear Investor relations programs are expected to kick in soon(hope with Korea news or government funding, $! is possible I think
Do your own DD and good luck investing


Bullboard Posts